- Growth-hormone secretagogues prompt the body to release its own growth hormone; the widely quoted dose figures derive largely from male-dominated research.
- This matters because the GH/IGF-1 axis is sex-dependent: women secrete more growth hormone spontaneously, and estrogen shifts how much IGF-1 that translates into.
- Tesamorelin is the exception, an FDA-approved secretagogue whose trials included women, while research compounds like ipamorelin and CJC-1295 have no established female-specific dosing.
The growth-hormone axis guide maps where these compounds act. This piece takes up the question that map raises but cannot answer: if secretagogue dosing was worked out mostly in men, what does that mean for a woman reading those same numbers? The short version is that the axis they act on is itself sex-dependent, which makes the quiet assumption of interchangeability exactly the kind this site exists to flag.
The compounds, briefly
- GHRH analogs, tesamorelin and CJC-1295 imitate the hypothalamic signal (GHRH) that tells the pituitary to release growth hormone.
- Ghrelin mimetics (GHRPs), ipamorelin works through a separate receptor to prompt the same release.
All of them are upstream nudges: they rely on the body's own pulsatile release rather than supplying growth hormone directly. That design is what makes the sex-dependence of the underlying axis so relevant.
Why sex changes the picture
Growth-hormone physiology is one of the more strongly sex-differentiated systems in endocrinology. Women secrete more growth hormone spontaneously than men, with different pulse patterns. And estrogen has a two-sided effect: it stimulates growth-hormone secretion while blunting the liver's IGF-1 response to it, an effect especially pronounced with oral estrogen. The upshot is that the same secretagogue signal can produce a different GH-and-IGF-1 result depending on a woman's estrogen status and even how she takes it.
Where the evidence actually stands
The compounds split into two groups. Tesamorelin is the exception worth knowing: it is FDA-approved (for HIV-associated lipodystrophy), and its clinical program included women, so there is real human data involving female participants. Ipamorelin and CJC-1295, by contrast, are research compounds without approved human indications; the dose figures that circulate for them come from small early studies and community convention, both male-weighted. For these, there is no established female-specific dose, and given the estrogen interaction above, 'use the male number' is an assumption, not a finding.
This site does not publish personal dosing for any compound, and the secretagogues are a clear illustration of why: the honest female-specific answer for the research compounds is that the data to set a dose doesn't exist. Any decision here belongs with a clinician, not a chart.
On each profile, that is what the female-evidence fields reflect, direct human data where it exists (as for tesamorelin), and extrapolated-or-unstudied where the female dose question has simply never been answered. Seeing which is which is the whole point.